Cargando…
Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development
The purpose of this article is to describe dependence and withdrawal phenomena related to CNS drugs discontinuation and to clarify issues related to the evaluation of clinical drug withdrawal and rebound as they relate to safety in new drug development. The article presents current understanding and...
Autores principales: | Lerner, Alicja, Klein, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425303/ https://www.ncbi.nlm.nih.gov/pubmed/32954266 http://dx.doi.org/10.1093/braincomms/fcz025 |
Ejemplares similares
-
Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015) -
Regulatory considerations for paediatric drug evaluation in China
por: Geng, Ying, et al.
Publicado: (2023) -
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
Publicado: (2018) -
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017) -
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations
por: Barry, Brian, et al.
Publicado: (2019)